<DOC>
	<DOCNO>NCT01788475</DOCNO>
	<brief_summary>Currently medication inject intravitreally previously vitrectomized eye short half-life due enhance clearance drug . The use Ozurdex implant may allow sustained level steroid delivery patient diabetic macular edema undergone prior vitrectomy . The sustained steroid level may lead improved central retinal thickness measurement improve visual acuity .</brief_summary>
	<brief_title>Safety Effectiveness Ozurdex Steroid Implants DME After Vitrectomy Surgery</brief_title>
	<detailed_description>A total 15 patient enrol study . This 3 year randomize control study primary endpoint 1 year . Secondary safety efficacy endpoint evaluate year 2 year 3 . Patients randomly enrol 1 3 group : Group 1 : Ozurdex administer every 3 month Group 2 : Ozurdex administer every 6 month Group 3 : Sham Ozurdex Patients evaluate monthly basis ETDRS visual acuity , intraocular pressure , fundus examination OCT. Ozurdex Sham Procedure perform Day 0 . All patient evaluate monthly thereafter . One month follow initial injection/sham , patient evaluate focal grid laser treatment investigator feels patient benefit . Re-implantation Ozurdex may occur time &gt; 3 month follow last injection group 1 &gt; 6 month follow last injection group 2 follow condition meet : 1 . Increase &gt; 50 micron best previous CRT measurement 2 . Recurrence intraretinal cystic edema 3 . Persistent intraretinal cystic edema At 13 month , patient sham group eligible Ozurdex implantation initial inclusion/exclusion criterion meet . These patient would follow re-implantation guideline group 2 ( every 6 month ) .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Adults &gt; 18 year age type 1 2 diabetes mellitus 2 . Patients DME secondary diabetes mellitus involve center macula OCT thickness &gt; 300 micron intraretinal cystic edema 3 . BCVA 20/40 20/400 4 . Patient vitrectomy surgery . 5 . Provide sign informed consent prior study procedure 1 . Patient unlikely benefit intravitreal Ozurdex due macular ischemia , atrophy , condition 2 . Patient history steroid response IOP &gt; 35 mm Hg requirement &gt; 2 glaucoma medication follow previous steroid injection . 3 . Previous injection antiVEGF steroid study eye within 90 day 4 . Vitrectomy , cataract surgery , YAG capsulotomy within 90 day . 5 . Current tractional detachment macula vitreous hemorrhage obscure detail macula . 6 . Pregnant , lactate female , female childbearing potential use reliable contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>Diabetic Macular Edema</keyword>
	<keyword>DME</keyword>
	<keyword>Pars Plana Vitrectomy</keyword>
</DOC>